Ibrutinib for the Treatment of AIHA in Patients With CLL/SLL or CLL-like MBL (NCT05694312) | Clinical Trial Compass
RecruitingPhase 2
Ibrutinib for the Treatment of AIHA in Patients With CLL/SLL or CLL-like MBL
Italy45 participantsStarted 2023-11-24
Plain-language summary
This is a multicenter, single arm, phase II study aimed at evaluating ibrutinib therapy for the treatment of AIHA in patients with CLL/SLL or CLL-like MBL.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Diagnosis of CLL/small lymphocytic lymphoma (SLL) or CLL-like monoclonal B-cell lymphocytosis (MBL) according to IWCLL guidelines.
✓. Patients \>18 years old
✓. Active AIHA (wAIHA or CAD) that i) is relapsed after previous treatment with corticosteroids (with or without rituximab), or ii) is steroid-resistant (failure to obtain hematologic response within 3 weeks on at least 1 mg/kg predniso(lo)ne), or iii) is steroid-dependent (need to continue on predniso(lo)ne at a dose of \>10 mg/day to maintain a response). AIHA is defined as: anemia (hemoglobin ≤10 g/dL; or hemoglobin \>10 g/dL dependent on transfusions to maintain this level of hemoglobin) and laboratory evidence of hemolysis (presence of 3 of 4 markers: increased reticulocyte count, increased indirect bilirubin, increased lactate dehydrogenase, decreased haptoglobin) and positive DAT (either IgG DAT, C3 DAT or both).
✓. Eligibility of patients with DAT-negative active AIHA should be confirmed by the Principal Investigator and co-Principal Investigator for the trial.
✓. Signed written informed consent according to ICH/EU/GCP and national local laws.
Exclusion criteria
✕. Contraindication to ibrutinib therapy as per treating physician's discretion.
✕. Contraindication to ibrutinib therapy as per ibrutinib data sheet (severe hepatic impairment, known allergy to the drug or to one of the excipients, concomitant treatment with warfarin or other vitamin K antagonists).
✕. Previous exposure to ibrutinib as CLL-directed therapy.
✕. Other CLL/SLL- or AIHA-directed treatment at the time of enrollment in the study, other than corticosteroids.
What they're measuring
1
Ibrutinib efficacy in terms of Overall response rate
Timeframe: at month 6
Trial details
NCT IDNCT05694312
SponsorGruppo Italiano Malattie EMatologiche dell'Adulto